Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis

• Published in: Scientific reports 2019-12, Vol.9 (1), p.20403-12, Article 20403
• Main Authors: Chou, Cheng-Wei, Lin, Ching-Heng, Hsiao, Tzu-Hung, Lo, Chia-Chien, Hsieh, Chih-Ying, Huang, Cheng-Chung, Sher, Yuh-Pyng
• Format: Article
• Language: English
• Subjects: 42/89; 631/67/1059/602; 631/67/1612/1350; 82/80; Adenocarcinoma; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - mortality; Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis - drug effects; Cardiovascular Diseases - prevention & control; Caspase; Cell Cycle - drug effects; Chemotherapy; Databases, Factual; Female; Humanities and Social Sciences; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Male; Medical prognosis; Membrane Microdomains - drug effects; Mevalonate pathway; Mevalonic acid; Middle Aged; Missense mutation; multidisciplinary; Mutants; p53 Protein; Population studies; Prognosis; Science; Science (multidisciplinary); Signal Transduction - drug effects; Simvastatin; Simvastatin - pharmacology; Statins; Survival Rate; Tumor Suppressor Protein p53 - genetics; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-56532-6

The p53 gene is an important tumour suppressor gene. Mutant p53 genes account for about half of all lung cancer cases. There is increasing evidence for the anti-tumour effects of statins via inhibition of the mevalonate pathway. We retrospectively investigated the correlation between statin use and lung cancer prognosis using the Taiwanese National Health Insurance Research Database, mainly focusing on early-stage lung cancer. This study reports the protective effects of statin use in early-stage lung cancer patients regardless of chemotherapy. Statin treatments reduced the 5-year mortality (odds ratio, 0.43; P